查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1493385

美國寡核苷酸合成市場規模、佔有率、趨勢分析報告：按產品/服務、按應用、按最終用途、細分市場預測，2024-2030

U.S. Oligonucleotide Synthesis Market Size, Share & Trends Analysis Report By Product & Service (Oligonucleotides, Equipment/Synthesizer), By Application (PCR Primers, Sequencing), By End-use, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10個工作天內

價格

美國寡核苷酸合成市場成長與趨勢：

根據Grand View Research, Inc.的最新報告，預計到2030年美國寡核苷酸合成市場規模將達到30.9億美元，預計2024年至2030年複合年成長率為12.80%。

由於分子診斷需求的增加、新應用的出現以及心血管疾病、視網膜疾病和癌症等難治性適應症的新機遇，預計寡核苷酸治療藥物的需求將在預測期內增加。酸合成的需求。

COVID-19大流行對美國寡核苷酸合成產業產生了積極影響。然而，在大流行期間，隨著製藥公司和醫療保健專業人員發現了寡核苷酸的更有效用途，並專注於其應用以遏制COVID-19 的傳播，對寡核苷酸合成的需求隨之增加。例如，創新基因組研究所在2020年表示，正在開發霧化、鎖定、核酸修飾的反義寡核苷酸，可以透過呼吸或霧化吸入來治療COVID-19感染。這些進步引起了醫療保健提供者的興趣。因此，疫情對美國市場產生了正面影響。

此外，該公司正在增加投資以開發基於寡核苷酸的療法。例如，2023年10月，GSK plc和Arrowhead Pharmaceuticals與強生公司旗下楊森製藥公司（Janssen）達成協議，獲得JNJ-3989的全球獨家開發和商業化權利，並宣布雙方已簽署協議。葛蘭素史克。楊森最初於 2018 年從 Arrowhead 引入了 JNJ-3989（以前稱為 ARO-HBV）。成熟製藥公司的類似舉措預計將在預測期內推動市場成長。

然而，儘管寡核苷酸合成是一個有前景的應用，但將其投入實用化仍有挑戰和問題。從合成中獲得高產率的最重要參數之一是監測偶聯效率。即使平均耦合中的小故障率也會對長序列產生巨大影響。平均耦合失效的微小變化會導致巨大的淨效應。因此，即時監控每個自訂化合成對於每個平台都至關重要，預計會在一定程度上阻礙市場成長。

美國寡核苷酸合成市場報告亮點

  • 2023年銷售佔有率為37.34%，服務在產品和服務領域佔據主導地位。這是由於對專業服務的需求不斷成長。隨著基因組研究和治療應用變得更加複雜，研究人員和公司擴大外包寡核苷酸序列的合成、精製和客製化。另一方面，預計寡核苷酸在預測期內將以最快的速度成長。
  • 在應用領域，PCR引子在2023年佔據最大的市場佔有率。專有的 PCR 引子使實驗室能夠檢測病原體中的微量 DNA 或 RNA，有助於識別包括病毒、細菌和寄生蟲感染在內的感染疾病。同時，定序預計在預測期內將以最快的速度成長。
  • 從最終用途來看，學術和研究機構在該領域佔據主導地位，2023 年收益佔有率最高，達 43.16%。這是由於學術研究機構進行的臨床研究數量的增加以及研究活動經費的增加。另一方面，製藥和生物技術公司預計在預測期內將以最快的複合年成長率成長。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章 市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 產業分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第4章美國寡核苷酸合成市場：產品與服務的商業分析

  • 細分儀表板
  • 美國寡核苷酸合成市場產品與服務波動分析
  • 2018-2030年美國寡核苷酸合成市場規模與趨勢分析（依產品與服務）
  • 寡核苷酸
  • 設備/合成設備
  • 試劑
  • 服務
    • DNA
    • RNA

第5章美國寡核苷酸合成市場：應用商業分析

  • 細分儀表板
  • 美國寡核苷酸合成市場應用變化分析
  • 2018-2030年美國寡核苷酸合成市場規模及趨勢分析（依應用）
  • PCR引子
  • PCR 檢測和麵板
  • 定序
  • DNA微陣列
  • 螢光原位雜合反應（FISH）
  • 反義寡核苷酸
  • 其他用途

第6章美國寡核苷酸合成市場：最終用途業務分析

  • 細分儀表板
  • 美國寡核苷酸合成市場的最終用途變化分析
  • 2018-2030年美國寡核苷酸合成市場規模與趨勢分析（依最終用途）
  • 學術研究所
  • 診斷實驗室
  • 製藥和生物技術公司

第7章 競爭狀況

  • 參與企業
  • 策略規劃
  • 2023 年企業市場分析
  • 參與企業概況
    • Thermo Fisher Scientific, Inc.
    • Merck KGaA
    • Danaher Corporation
    • Dharmacon Inc.
    • Agilent Technologies
    • Bio-synthesis
    • LGC Biosearch Technologies
    • Twist Bioscience
    • TriLink BioTechnologies
    • Genscript
Product Code: GVR-4-68040-290-5

U.S. Oligonucleotide Synthesis Market Growth & Trends:

The U.S. oligonucleotide synthesis market size is anticipated to reach USD 3.09 billion by 2030 and is projected to grow at a CAGR of 12.80% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising demand for molecular diagnostics, emerging novel applications, and growing demand for oligonucleotide therapeutics owing to the emerging potential for incurable indications such as cardiovascular diseases, retinal disorders, and cancer are anticipated to increase the demand for oligonucleotide synthesis over the forecast period.

The COVID-19 pandemic has had a positive impact on the U.S. oligonucleotide synthesis industry. During the pandemic, however, the demand for oligonucleotide synthesis grew as pharmaceutical companies and healthcare professionals focused on identifying more efficient usage of oligonucleotides and their application to limit the spread of COVID-19. For instance, the Innovative Genomic Institute stated in 2020 that it was developing an aerosolized, locked nucleic acid modifying antisense oligonucleotide that can be breathed or nebulized to treat COVID-19 infection. Such advances piqued the interest of healthcare providers. Hence, the pandemic has had a favorable impact on the U.S. market.

Moreover, companies have increased investments to develop oligonucleotide-based therapeutics. For instance, in October 2023, GSK plc and Arrowhead Pharmaceuticals announced a contract with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to assign GSK the exclusive worldwide rights to develop and commercialize JNJ-3989. Janssen initially in-licensed JNJ-3989 (previously ARO-HBV) from Arrowhead in 2018. Similar initiatives by well-established pharmaceutical companies are anticipated to drive market growth over the forecast period.

However, oligonucleotide synthesis encounters challenges and problems in practical applications, even with high-potential applications. One of the most critical parameters to get a high yield from synthesis is monitoring its coupling efficiency. Even the slightest rate of failure in average coupling causes dramatic effects in long sequences. A minor change in average coupling failure leads to a substantial net effect. Thus, real-time monitoring of each custom synthesis becomes essential for every platform and, thereby, is anticipated to hamper the growth of the market to a certain extent.

U.S. Oligonucleotide Synthesis Market Report Highlights:

  • Services dominated the product & service segment with the largest revenue share of 37.34% in 2023. This is attributed to the growing demand for specialized services. As the complexity of genomic research and therapeutic applications increases, researchers & companies are turning to outsourcing for the synthesis, purification, and customization of oligonucleotide sequences. On the other hand, oligonucleotide are expected to grow at the fastest rate over the forecast period.
  • The PCR primers held the largest market share in 2023 for the application segment. Unique PCR primer allows labs to detect tiny quantities of DNA or RNA from pathogens, assisting in the identification of infectious diseases, including viral, bacterial, and parasitic infections. On the other hand, sequencing is expected to grow at the fastest rate over the forecast period.
  • Based on end use, academic research institutes dominated the segment with the largest revenue share of 43.16% in 2023. This is attributed to the increasing number of clinical studies, which are being conducted in academic institutes and the growing funding for research activities. On the other hand, pharmaceutical & biotechnology companies are anticipated to grow at the fastest CAGR over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Product & Service
    • 1.2.2. Application
    • 1.2.3. End-use
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Strong pipeline of oligonucleotide therapeutics in clinical trials
      • 3.2.1.2. High R&D spending of pharmaceutical & biotechnology companies
      • 3.2.1.3. Technological advancements in gene editing technologies
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Need for advanced oligo synthesis solutions
      • 3.2.2.2. High cost associated with genomics research
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Oligonucleotide Synthesis Market: Product & Service Business Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Oligonucleotide Synthesis Market Product & Service Movement Analysis
  • 4.3. U.S. Oligonucleotide Synthesis Market Size & Trend Analysis, by Product & Service, 2018 to 2030 (USD Million)
  • 4.4. Oligonucleotides
    • 4.4.1. Oligonucleotides market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.1. DNA
      • 4.4.1.1.1. DNA market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.1.2. Column-based
      • 4.4.1.1.2.1. Column-based market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.1.3. Array-based
      • 4.4.1.1.3.1. Array-based market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.2. RNA
      • 4.4.1.2.1. RNA market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.2.2. By Technology
      • 4.4.1.2.2.1. Column-based
      • 4.4.1.2.2.1.1. Column-based market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.2.2.2. Array-based
      • 4.4.1.2.2.2.1. Array-based market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.2.3. By Type
      • 4.4.1.2.3.1. Short RNA Oligos (<65 nt)
      • 4.4.1.2.3.1.1. Short RNA oligos (<65nt) market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.2.3.2. Long RNA Oligos (>65 nt)
      • 4.4.1.2.3.2.1. Long RNA oligos (>65 nt) market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.2.3.3. CRISPR (sgRNA)
      • 4.4.1.2.3.3.1. CRISPR (sgRNA) market estimates and forecast, 2018 - 2030 (USD Million
  • 4.5. Equipment/Synthesizer
    • 4.5.1. Equipment/synthesizer market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.6. Reagents
    • 4.6.1. Reagents market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.7. Services
    • 4.7.1. Services market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.7.2. DNA
      • 4.7.2.1. DNA market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.2.2. Custom Oligo Synthesis Services
      • 4.7.2.2.1. 25 nmol
      • 4.7.2.2.1.1. 25 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.2.2.2. 50 nmol
      • 4.7.2.2.2.1. 50 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.2.2.3. 200 nmol
      • 4.7.2.2.3.1. 200 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.2.2.4. 1000 nmol
      • 4.7.2.2.4.1. 1000 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.2.2.5. 10000 nmol
      • 4.7.2.2.5.1. 10000 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.2.3. Modification Services
      • 4.7.2.3.1. Modification services market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.2.4. Purification Services
      • 4.7.2.4.1. Purification services market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.7.3. RNA
      • 4.7.3.1. RNA market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.3.2. Custom Oligo Synthesis Services
      • 4.7.3.2.1. 25 nmol
      • 4.7.3.2.1.1. 25 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.3.2.2. 100 nmol
      • 4.7.3.2.2.1. 100 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.3.2.3. 1000 nmol
      • 4.7.3.2.3.1. 1000 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.3.2.4. 10000 nmol
      • 4.7.3.2.4.1. 10000 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.3.3. Modification Services
      • 4.7.3.3.1. Modification services market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.3.4. Purification Services
      • 4.7.3.4.1. Purification services market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 5. U.S. Oligonucleotide Synthesis Market: Application Business Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Oligonucleotide Synthesis Market Application Movement Analysis
  • 5.3. U.S. Oligonucleotide Synthesis Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. PCR Primer
    • 5.4.1. PCR primer market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.5. PCR Assay & Panel
    • 5.5.1. PCR assay & panel market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.6. Sequencing
    • 5.6.1. Sequencing market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.7. DNA Microarrays
    • 5.7.1. DNA microarrays market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.8. Fluorescence In Situ Hybridization (FISH)
    • 5.8.1. Fluorescence in situ hybridization (FISH) market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.9. Antisense Oligonucleotides
    • 5.9.1. Antisense oligonucleotides market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.10. Other Applications
    • 5.10.1. Other applications market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6. U.S. Oligonucleotide Synthesis Market: End-use Business Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Oligonucleotide Synthesis Market End-use Movement Analysis
  • 6.3. U.S. Oligonucleotide Synthesis Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
  • 6.4. Academic Research Institutes
    • 6.4.1. Academic research institutes market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5. Diagnostic Laboratories
    • 6.5.1. Diagnostic laboratories market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.6. Pharmaceutical & Biotechnology Companies
    • 6.6.1. Pharmaceutical & biotechnology companies market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market Position Analysis, 2023
  • 7.4. Participant's Overview
    • 7.4.1. Thermo Fisher Scientific, Inc.
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product & service benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Merck KGaA
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product & service benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Danaher Corporation
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product & service benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Dharmacon Inc.
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product & service benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Agilent Technologies
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product & service benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Bio-synthesis
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product & service benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. LGC Biosearch Technologies
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product & service benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Twist Bioscience
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product & service benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. TriLink BioTechnologies
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product & service benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Genscript
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product & service benchmarking
      • 7.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 4 U.S. oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 5 U.S. oligonucleotide synthesis market, by end-use, 2018 - 2030 (USD Million)
  • Table 6 Participant's overview
  • Table 7 Financial performance
  • Table 8 Key companies undergoing expansions
  • Table 9 Key companies undergoing acquisitions
  • Table 10 Key companies undergoing collaborations
  • Table 11 Key companies launching new products/services
  • Table 12 Key companies undertaking other strategies

List of Figures

  • Fig. 1 U.S. oligonucleotide synthesis market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market outlook
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Parent market outlook
  • Fig. 13 U.S. oligonucleotide synthesis market driver analysis
  • Fig. 14 U.S. oligonucleotide synthesis market restraint analysis
  • Fig. 15 U.S. oligonucleotide synthesis market: Porter's analysis
  • Fig. 16 U.S. oligonucleotide synthesis market: Product & service outlook key takeaways
  • Fig. 17 U.S. oligonucleotide synthesis market: Product & service movement analysis
  • Fig. 18 Oligonucleotides market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 DNA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Column-based market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Array-based market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 RNA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Column-based market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Array-based market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Short RNA oligos (<65 nt) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Long RNA oligos (>65 nt) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 CRISPR (sgRNA) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Equipment/synthesizer market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Reagents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 DNA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Custom oligo synthesis services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 25 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 50 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 200 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 1000 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 10000 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Modification services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Purification services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 RNA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Custom oligo synthesis services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 25 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 100 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 1000 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 10000 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Modification services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Purification services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 U.S. oligonucleotide synthesis market: Application movement analysis
  • Fig. 49 U.S. oligonucleotide synthesis market: Application outlook and key takeaways
  • Fig. 50 PCR primers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 PCR assays & panels market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Sequencing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 DNA microarrays market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Fluorescence in situ hybridization (FISH) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Antisense oligonucleotides market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 56 Other applications market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 U.S. oligonucleotide synthesis market End-use outlook key takeaways
  • Fig. 58 U.S. oligonucleotide synthesis market: End-use movement analysis
  • Fig. 59 Academic research institutes market estimates and forecast, 2018 - 2030 (USD Million))
  • Fig. 60 Diagnostic laboratories market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Pharmaceutical & biotechnology companies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Key company categorization
  • Fig. 63 Company market positioning
  • Fig. 64 Market participant categorization
  • Fig. 65 Strategy framework